Languages
简体中文
繁體中文
English
日本語
한국어
Bahasa Indonesia
Tiếng Việt
Sign In
Send a Release
Products
News
Resources
Contact
Search
Search
Products
News
Resources
Contact
Overview
Content Creation
Distribution
Monitoring & Insights
Influencer Database
Falcon
All Products
Send a Release
News
Products
Resources
Contact
Overview
Latest
Regional
Mainland China
Japan
Korea
Indonesia
Malaysia
Singapore
Thailand
Vietnam
Australia
Industry
Auto & Transportation
Business Technology
Consumer Products & Retail
Consumer Technology
Energy
Entertainment & Media
Environment
Financial Services
General Business
Health
Heavy Industry & Manufacturing
Policy & Public Interest
Sports
Telecommunications
Travel
Food and Beverages
Advertising, Marketing and Media
Exhibition
Real Estate and Furniture
Trending Topics
Personnel Announcements
Earnings
New Technologies & New Products
Investment & Financing
Carbon Neutral
China International Consumer Products Expo
Olympics
Summer Event
Environmental, Social, Governance (ESG)
Sustainability
Embedded World
Belt & Road
Artificial Intelligence
Holiday Season
Consumer Electronics Show (CES)
Earth Day
Blockchain
Mother's Day
China International Import Expo
5G
Multimedia
Other Languages
Malaysian
Thai
Public Company News
Send a Release
Resources
Products
News
Contact
Overview
Beyond PR Blog
Media Coffee
Client Stories
White Papers
Events in APAC
Media Room
Send a Release
Contact
Products
Resources
News
Asia Pacific Offices
Request More Information
Alert / Newsletter Subscription
Our Presence on Social Media Sites
FAQs
Send a Release
Products
News
Resources
Contact
Send a Release
ABBISKO THERAPEUTICS上海和誉生物
Media Room
Latest News
Photo News
Photo News
Time
All
2024
2023
2022
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting
2023-05-28 21:00
2846
Report
Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting
2023-04-17 08:30
3092
Report
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial
2023-03-16 10:00
2997
Report
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib(ABSK021)
2023-01-30 11:00
3060
Report
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
2022-07-04 13:34
1897
Report
Share:
Share to wechat: